artificial intelligence
Tempus Signs $200M Deal With AstraZeneca, Pathos AI to Develop Multimodal Cancer Foundation Model
The collaboration, under which Tempus will collect data licensing and model development fees, will leverage its repository of de-identified multimodal patient data.
Biostate AI, Weill Cornell Partner on Leukemia Precision Medicine Project
The partners aim to develop AI models to stratify AML subtypes, make disease prognoses, and help select personalized therapies.
ConcertAI, Bayer Partner to Leverage Patient Data for Precision Oncology Insights
The firms will explore molecular mechanisms and patient responses in cancer to inform development of new therapies.
Ono Pharmaceutical Taps Jorna Therapeutics for RNA-Editing Drug Discovery Partnership
Ono has an exclusive option to discover, develop, and commercialize drug candidates based on RNA-editing drug sequences designed by Jorna.
BeiGene Partners With nFerence to Explore Treatment Patterns in B-cell Cancers
The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.
Mar 27, 2025
Mar 12, 2025